The Technical Analyst
Cullinan Oncology, LLC [CGEM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cullinan Oncology, LLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.21% $26.57
America/New_York / 10 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 144.25 mill |
| EPS: | -3.69 |
| P/E: | -7.20 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 43.07 mill |
| Avg Daily Volume: | 0.724 mill |
| RATING 2024-05-10 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.20 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.22x |
| Company: PE -7.20 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.28 (-91.41%) $-24.29 |
| Date: 2024-05-10 |
| Expected Trading Range (DAY) |
|---|
|
$ 25.20 - 27.94 ( +/- 5.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-06 | Michaelson Jennifer | Buy | 50 000 | Common Stock |
| 2024-05-06 | Michaelson Jennifer | Sell | 37 723 | Common Stock |
| 2024-05-06 | Michaelson Jennifer | Sell | 50 000 | Stock Option (Right to Buy) |
| 2024-05-07 | Michaelson Jennifer | Buy | 5 606 | Common Stock |
| 2024-05-07 | Michaelson Jennifer | Sell | 5 606 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 54.99 |
| Last 99 transactions |
| Buy: 2 506 121 | Sell: 594 695 |
Forecast:
16:00 - $26.52
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $26.52
Forecast 2: 16:00 - $26.52
Forecast 3: 16:00 - $26.52
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $26.57 (-2.21% ) |
| Volume | 0.584 mill |
| Avg. Vol. | 0.724 mill |
| % of Avg. Vol | 80.69 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CGEM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $17.88 | N/A | Active |
|---|
CGEM
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-29 07:00:00 - Press Release
Cullinan Therapeutics Announces Appointment Of Mary Kay Fenton As Chief Financial Officer
Cambridge, mass., april 29, 2024 (globe newswire) -- cullinan therapeutics, inc. (nasdaq: cgem), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of mary kay fenton as chief financial officer, beginning april 29.
2024-04-24 10:09:00 - Press Release
Cullinan Therapeutics To Present Clinical Data From Phase 1 Study Evaluating Novel Anti-mica/b Antibody, Cln-619, As Monotherapy And In Combination With A Checkpoint Inhibitor In Patients With Advanced Solid Tumors At Asco 2024
Cambridge, mass., april 24, 2024 (globe newswire) -- cullinan therapeutics, inc. (nasdaq: cgem), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its phase 1 trial of cln-619 in patients with advanced solid tumors will be presented at the 2024 american society of clinical oncology (asco) annual meeting taking place in chicago from may 31-june 4, 2024. the data will include first results from the dose escalation cohort of cln-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.
2024-04-16 07:00:00 - Press Release
Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases
Cln-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication
2024-04-16 06:59:00 - Press Release
Cullinan Therapeutics Announces Oversubscribed $280 Million Private Placement
Financing includes new and existing leading life sciences institutional investors proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 cullinan to host a virtual investor event on april 16 at 8:00 am et cambridge, mass., april 16, 2024 (globe newswire) -- cullinan therapeutics, inc. (formerly cullinan oncology, inc.) (nasdaq: cgem; “cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19...
2024-03-14 07:00:00 - Press Release
Cullinan Oncology Provides Corporate Update And Reports Fourth Quarter And Full Year 2023 Financial Results
Cullinan remains on track to report additional solid tumor dose escalation data for cln-619 in the second quarter of 2024 and recently received fda clearance for an ind to evaluate cln-619 in relapsed/refractory multiple myeloma
Latest News
2024-04-24 10:09:00 - GlobeNewsWire
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.
2023-12-18 16:53:00 - GlobeNewsWire
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed's presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).
2023-10-30 08:00:00 - GlobeNewsWire
Cullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
2023-07-31 08:00:00 - GlobeNewsWire
Cullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
2023-06-09 16:07:00 - The Motley Fool
Why Shares of Cullinan Oncology Jumped This Week
Cullinan Oncology's lead therapy is zipalertinib, which is in a trial to treat non-small cell lung cancer. The company has a deep pipeline and published encouraging news regarding preclinical candidate CLN-619 as a pan-cancer treatment.
2023-05-25 17:00:00 - GlobeNewsWire
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy
2023-04-26 10:08:00 - GlobeNewsWire
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid tumors will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 2-6.
2023-03-14 16:35:00 - GlobeNewsWire
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial clinical data from the ongoing trial is on-track to be released mid-2023.
2022-11-01 07:00:00 - GlobeNewsWire
Cullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that its management team will participate in the following investor conferences.
2022-09-22 06:16:27 - Seeking Alpha
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after.